Drug profile · INN
tradipitant
NEREUS
tradipitant (NEREUS) is a neurokinin 1 receptor antagonist. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
Drug details — tradipitant
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 10
- Data quality
- 0.89
Quick answer
tradipitant (NEREUS) is a neurokinin 1 receptor antagonist. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Neurokinin 1 receptor antagonist
Primary target: Substance-P receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12318375
Method of treatment with tradipitant
granted -
US 11549147
Treatment of atopic dermatitis with tradipitant
granted -
US 11324735
Method of treatment with tradipitant
granted -
US 10821099
Use of tradipitant in motion sickness
granted -
US 10772880
Method of treatment with tradipitant
granted -
US 10463655
Method of treatment with tradipitant
granted
Frequently asked questions
What is tradipitant?
tradipitant (NEREUS) is a neurokinin 1 receptor antagonist. Associated with Vanda Pharmaceuticals Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tradipitant?
NEREUS is a marketed brand name for tradipitant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tradipitant?
tradipitant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.